WallStreetZenWallStreetZen

NASDAQ: ITOS
Iteos Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ITOS

Based on 2 analysts offering 12 month price targets for Iteos Therapeutics Inc.
Min Forecast
$27.00+49.58%
Avg Forecast
$36.50+102.22%
Max Forecast
$46.00+154.85%

Should I buy or sell ITOS stock?

Based on 2 analysts offering ratings for Iteos Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ITOS stock forecasts and price targets.

ITOS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-13
lockedlocked$00.00+00.00%2024-03-12

1 of 1

Forecast return on equity

Is ITOS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.27%

Forecast return on assets

Is ITOS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ITOS revenue forecast

What is ITOS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$56.3M
Avg 2 year Forecast
$20.3M
Avg 3 year Forecast
$154.8M

ITOS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ITOS$18.05$36.50+102.22%Strong Buy
EXAI$5.20$8.00+53.85%Hold
GHRS$12.60$36.67+191.01%Strong Buy
MLYS$13.00$30.00+130.77%Strong Buy
ZYME$9.12$12.67+38.89%Strong Buy
View Top Biotech Stocks

Iteos Therapeutics Stock Forecast FAQ

Is Iteos Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ITOS) stock is to Strong Buy ITOS stock.

Out of 2 analysts, 1 (50%) are recommending ITOS as a Strong Buy, 1 (50%) are recommending ITOS as a Buy, 0 (0%) are recommending ITOS as a Hold, 0 (0%) are recommending ITOS as a Sell, and 0 (0%) are recommending ITOS as a Strong Sell.

If you're new to stock investing, here's how to buy Iteos Therapeutics stock.

What is ITOS's revenue growth forecast for 2024-2026?

(NASDAQ: ITOS) Iteos Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Iteos Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ITOS's revenue for 2024 to be $2,033,720,509, with the lowest ITOS revenue forecast at $455,148,817, and the highest ITOS revenue forecast at $3,612,292,200. On average, 2 Wall Street analysts forecast ITOS's revenue for 2025 to be $733,475,931, with the lowest ITOS revenue forecast at $115,593,350, and the highest ITOS revenue forecast at $1,351,358,512.

In 2026, ITOS is forecast to generate $5,590,853,007 in revenue, with the lowest revenue forecast at $927,275,408 and the highest revenue forecast at $12,419,060,584.

What is ITOS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ITOS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ITOS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ITOS price target, the average ITOS price target is $36.50, with the highest ITOS stock price forecast at $46.00 and the lowest ITOS stock price forecast at $27.00.

On average, Wall Street analysts predict that Iteos Therapeutics's share price could reach $36.50 by May 13, 2025. The average Iteos Therapeutics stock price prediction forecasts a potential upside of 102.22% from the current ITOS share price of $18.05.

What is ITOS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ITOS) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.